The NGS TP53 Mutation Analysis Test, available at DNA Labs UAE for a cost of 42,000 AED, is a sophisticated genetic testing procedure designed to identify mutations in the TP53 gene. This gene plays a crucial role in regulating cell division and preventing the development of tumors, making its analysis vital for understanding individual cancer risks and for the diagnosis of certain genetic disorders, such as Li-Fraumeni syndrome. Utilizing Next-Generation Sequencing (NGS) technology, the test offers a comprehensive examination of the TP53 gene, allowing for the detection of both known and novel mutations with high precision and accuracy. The results from this test can provide essential information for personalized treatment planning, including decisions regarding surveillance, surgery, chemotherapy, or radiation therapy, enhancing the potential for positive patient outcomes. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, the NGS TP53 Mutation Analysis Test represents a significant advancement in the field of personalized medicine and genetic diagnostics.
The Oncomine Comprehensive Plus Panel Test is a cutting-edge genetic test designed to provide a comprehensive analysis of cancer-related genes. This test, performed by DNA Labs UAE, is aimed at identifying genetic mutations and alterations in a wide array of genes associated with different types of cancer. With a cost of 39,000 AED, it offers an extensive assessment that helps in guiding personalized treatment plans for cancer patients.
The test utilizes next-generation sequencing (NGS) technology to examine a broad panel of genes for mutations that could influence a patient’s response to certain cancer therapies, making it an invaluable tool in the realm of precision medicine. By pinpointing specific genetic mutations, healthcare providers can tailor treatments to the individual’s genetic profile, potentially improving outcomes and minimizing unnecessary side effects.
The Oncomine Comprehensive Plus Panel Test is particularly useful for patients with advanced or difficult-to-treat cancers, where conventional treatment options may have been exhausted or are deemed less effective. The insights gained from this test can lead to the identification of targeted therapies and clinical trial opportunities that are most likely to benefit the patient based on their unique genetic makeup.
DNA Labs UAE, known for its state-of-the-art facilities and expertise in genetic testing, ensures that the test is conducted with the highest standards of accuracy and reliability. Their team of specialized geneticists and clinicians work closely with patients and healthcare providers to interpret the results and integrate them into the patient’s care plan.
In summary, the Oncomine Comprehensive Plus Panel Test offered by DNA Labs UAE is a significant advancement in cancer care, providing a deeper understanding of the genetic underpinnings of an individual’s cancer and opening up personalized treatment avenues. With its comprehensive approach and the high cost reflective of its extensive analysis, it represents a crucial step forward in the fight against cancer.
The Oncopro Liquid Biopsy Test is a cutting-edge diagnostic tool offered by DNA Labs UAE, designed to detect and monitor various types of cancers through a non-invasive method. This innovative test requires only a blood sample from the patient, making it a less intrusive option compared to traditional biopsy methods that require tissue samples. The liquid biopsy technique focuses on analyzing circulating tumor DNA (ctDNA) present in the blood, which sheds from the tumor, allowing for the identification of genetic mutations and alterations associated with cancer.
With a cost of 38,610 AED, the Oncopro Liquid Biopsy Test represents a significant investment in personal health care, offering a valuable resource for early detection, treatment planning, and monitoring of cancer progression or response to treatment. The test is particularly beneficial for patients who are unable to undergo conventional biopsy procedures due to health constraints or for cancers that are difficult to access. By providing detailed insights into the molecular profile of a patient’s cancer, the Oncopro Liquid Biopsy Test enables personalized treatment strategies, potentially improving outcomes and quality of life for cancer patients.
DNA Labs UAE, as the provider of this test, underscores its commitment to leveraging advanced genetic testing technologies to support cancer care. The test is part of a broader movement towards precision medicine, where treatments can be tailored to the individual characteristics of each patient’s disease, offering a more targeted and effective approach to cancer treatment.
The Non-Invasive Prenatal Paternity (NIPT) DNA Test is a groundbreaking procedure offered by DNA Labs UAE, designed to determine paternity with high accuracy during pregnancy. This test is non-invasive, meaning it poses no risk to the mother or the unborn child, as it requires only a blood sample from the expectant mother and a simple swab from the potential father. The test works by analyzing the baby’s DNA found within the mother’s bloodstream, comparing it to the DNA of the potential father. This advanced technology can be performed as early as the 7th week of pregnancy, providing early and reliable answers about paternity.
The cost of the NIPT Pregnancy Paternity DNA Test at DNA Labs UAE is 7000 AED. This price reflects the sophisticated technology and expertise required to accurately analyze and interpret the results. Opting for this test at DNA Labs UAE ensures a high level of accuracy, confidentiality, and professional support throughout the process. This option is particularly appealing for families seeking early paternity confirmation, without the risks associated with invasive testing methods.
The Oncomine Comprehensive Panel, along with the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 Test, is an advanced genetic testing suite designed for a comprehensive analysis of cancer genomes. Offered by DNA Labs in the UAE, this suite of tests provides a detailed overview of the genetic alterations in tumors, aiding in the personalized treatment of cancer patients.
The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that identifies DNA and RNA changes across a wide array of cancer-related genes. This broad-spectrum analysis helps in understanding the molecular underpinnings of an individual’s cancer, facilitating targeted therapy decisions.
The Oncomine TMB test quantifies the total number of mutations within a tumor genome, providing an index of the tumor’s mutation burden. A high TMB is often associated with better responses to immunotherapies, making this test crucial for therapy selection.
The MSI test assesses the status of microsatellite instability in cancer cells, which is a condition of genetic hypermutability that results from the impairment of DNA mismatch repair. MSI status is a key biomarker in certain types of cancers, such as colorectal cancer, and influences treatment choices.
The PD-L1 test measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 is a checkpoint protein that helps cancers evade the immune system. Knowing the PD-L1 status can guide the use of checkpoint inhibitor therapies, which can be effective in treating various types of cancer.
Conducted at DNA Labs in the UAE, the comprehensive suite of these tests is priced at 24,000 AED. This investment in precision medicine can significantly impact treatment strategies, offering hope for better outcomes by tailoring therapies to the specific genetic profile of a patient’s tumor.
The “Oncopro NCCN Lung Cancer Panel with PD-L1 Test” is a comprehensive diagnostic tool utilized in the assessment and management of lung cancer, adhering to the guidelines set by the National Comprehensive Cancer Network (NCCN). This advanced panel is designed to analyze a wide array of genetic markers associated with lung cancer, offering insights into the molecular profile of the tumor. This information is crucial for determining the most effective treatment strategies, including targeted therapies and immunotherapies.
A significant component of this panel is the PD-L1 test, which measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 plays a key role in suppressing the immune system and allowing cancer cells to evade detection and destruction by immune cells. Understanding the PD-L1 status of a tumor can guide oncologists in selecting immunotherapy treatments, which can be more effective for patients with high PD-L1 expression.
The test is available at DNA Labs UAE, a leading diagnostic facility known for its state-of-the-art technology and expertise in genetic and molecular testing. The cost of the “Oncopro NCCN Lung Cancer Panel with PD-L1 Test” at DNA Labs UAE is 28,080 AED. Given the complexity and the detailed insights it provides into the genetic makeup of lung cancer, this test represents a valuable investment in personalized cancer care, enabling tailored treatment plans that can significantly improve patient outcomes.
The Sarcoma Gene Panel Test, offered at DNA Labs UAE for a cost of 22,500 AED, is a specialized genetic test designed to identify mutations in a set of genes associated with the development of sarcoma, a type of cancer that arises from transformed cells of mesenchymal origin. This comprehensive test is crucial for the accurate diagnosis, prognosis, and determination of targeted therapies for patients with sarcoma. By analyzing multiple genes simultaneously, this panel test can provide a detailed genetic profile of the tumor, helping healthcare professionals to tailor treatment plans according to the specific genetic alterations present in the cancer cells. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test is a vital tool in the fight against sarcoma, offering hope for more effective and personalized treatment options for patients.
The Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) Test are advanced genomic profiling assays used in the field of oncology to aid in the personalized treatment of cancer. Conducted at DNA Labs UAE, these tests are designed to identify a wide array of genetic mutations, alterations, and biomarkers across various cancer types.
The Oncomine Comprehensive Panel focuses on analyzing a broad set of genes known to be involved in cancer progression and response to treatments. This helps in pinpointing specific genetic changes in a patient’s tumor, enabling healthcare providers to tailor treatment strategies based on the unique genetic makeup of the cancer.
The Oncomine TMB and MSI Test complements this by measuring the tumor mutation burden and the microsatellite instability in the cancer cells. TMB is an indicator of the number of mutations within the genome of a tumor, which can predict response to immunotherapy. MSI status is a marker for defects in the DNA repair mechanisms, also informing treatment choices, particularly with immunotherapy.
Offered at a cost of 21000 AED, these tests at DNA Labs UAE represent a significant investment in personalized cancer care, allowing for more targeted and potentially effective treatments. By combining the insights from both the comprehensive panel and the TMB and MSI tests, oncologists can make informed decisions to optimize patient outcomes.
The Amyloid Protein Identification Test is a specialized diagnostic procedure conducted to detect the presence of amyloid proteins in the body. Amyloid proteins are abnormal proteins that can accumulate in tissues and organs, leading to a group of diseases known as amyloidosis. These diseases can affect various parts of the body, including the heart, kidneys, liver, and nervous system, impairing their function.
This test is particularly crucial for individuals who exhibit symptoms suggestive of amyloidosis or those with a family history of the condition. Early detection through the Amyloid Protein Identification Test can facilitate timely intervention, potentially improving patient outcomes.
The test involves collecting a sample from the patient, which is then analyzed in a laboratory setting to identify the presence and type of amyloid proteins. This information is vital for determining the appropriate course of treatment.
Conducted at DNA Labs UAE, a leading facility known for its advanced diagnostic technologies and expert medical staff, the test ensures accuracy and reliability. The cost of the Amyloid Protein Identification Test at DNA Labs UAE is 24,570 AED. While the price might seem high, the test’s potential to significantly impact patient care and treatment planning makes it a valuable diagnostic tool in managing amyloidosis.
The Oncopro NCCN Lung Cancer Panel Test, available at DNA Labs UAE, is a cutting-edge diagnostic tool designed to aid in the personalized treatment of lung cancer. This comprehensive test, priced at 23,400 AED, employs next-generation sequencing technology to analyze a patient’s tumor sample for specific genetic mutations and biomarkers identified by the National Comprehensive Cancer Network (NCCN) guidelines as relevant to lung cancer care. By pinpointing these unique genetic alterations, the test enables healthcare providers to tailor treatment strategies to the individual patient, potentially improving outcomes and reducing the likelihood of unnecessary side effects. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in the precision medicine approach to lung cancer treatment, offering hope for more effective and personalized care.
